BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Should l Buy BRTX?
Source: SeekingAlpha
Revenue $25,000 (down from $35,000), a decrease of 29% year-over-year due to timing differences in revenue recognition.
Deferred Revenue $150,000 (compared to $0), indicating a positive momentum in underlying revenue fundamentals.
Loss from Operations $4.8 million (up from $4.1 million), an increase of 17% year-over-year due to increased operational costs.
Net Loss $5.3 million or $0.64 per share (compared to a net loss of $2.2 million or $0.33 per share), an increase attributed to a gain on the exchange of warrants in Q1 2024.
Cash Used in Operating Activities $2.8 million, reflecting ongoing operational expenditures.
Cash, Cash Equivalents and Marketable Securities $9.1 million, indicating a strong financial position with no outstanding debt.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BRTX
Wall Street analysts forecast BRTX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.213
Low
8.00
Averages
8.00
High
8.00
Current: 0.213
Low
8.00
Averages
8.00
High
8.00
No data
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
BioRestorative Secures Patent Protection in Australia
- Patent Protection Enhanced: BioRestorative has received approval from IP Australia for its patent application covering the method of creating three-dimensional brown adipose-derived stem cell aggregates, further solidifying its market position in obesity and metabolic disease treatments.
- Technological Advantages Revealed: This patent provides the broadest protection for BioRestorative's ThermoStem® technology, aimed at developing safer and more effective cell-based therapies compared to GLP-1 drugs, showcasing the company's competitive potential in the rapidly growing therapeutic market.
- Global Strategic Expansion: CEO Lance Alstodt emphasized that securing this patent is a significant step in expanding the company's global IP portfolio, aimed at enhancing its leadership in stem cell therapies through continuous technological innovation and market protection.
- Clinical Trial Progress: BioRestorative is conducting a Phase 2 clinical trial for BRTX-100 targeting chronic lower back pain, and with the newly acquired patent, it is expected to accelerate its commercialization process in the regenerative medicine field.
See More
BioRestorative Closes Public Offering of 14.29 Million Shares
- Successful Public Offering: BioRestorative Therapies has closed its public offering of 14,285,715 shares at a price of $0.35 per share, raising approximately $5 million in gross proceeds, which reflects the company's funding needs and market confidence in the regenerative medicine sector.
- Clear Use of Proceeds: The net proceeds will be allocated to clinical trials for BRTX-100, pre-clinical research for the ThermoStem Program, and the development of its commercial biocosmeceuticals platform, indicating a strategic focus on product diversification and technological innovation.
- Regulatory Compliance: The registration statement for this offering was declared effective by the SEC on February 11, 2026, ensuring transparency and legality, which helps to enhance investor confidence in the company's operations.
- Broad Market Prospects: BioRestorative's lead product BRTX-100 is currently in Phase 2 clinical trials for chronic lower back pain, and with FDA IND clearance, it signals potential market opportunities and future growth in the regenerative medicine field.
See More
BioRestorative Closes $5 Million Public Offering of 14.3 Million Shares
- Funding Amount: BioRestorative successfully closed a public offering of 14.3 million shares, raising approximately $5 million in gross proceeds, which will be allocated to clinical trials for BRTX-100 and other R&D projects, thereby enhancing its competitive position in the regenerative medicine sector.
- Equity Structure: The offering was priced at $0.35 per share, with accompanying warrants issued at the same price, which are immediately exercisable and will expire in five years, providing the company with flexibility for future capital operations.
- Clinical Trial Progress: The company has initiated a Phase 2 clinical trial for BRTX-100 aimed at treating chronic lower back pain due to degenerative disc disease, which is expected to create new market opportunities for its product line and further drive company growth.
- Biopharmaceutical Platform: BioRestorative is also developing the ThermoStem program, utilizing brown adipose-derived stem cells to target obesity and metabolic disorders, with preliminary research indicating potential benefits in increasing caloric expenditure and reducing glucose and lipid levels, showcasing a broad market potential.
See More
U.S. Stocks Decline Midway, Nasdaq Drops Over 350 Points
- Market Performance: U.S. stocks traded lower midway through Thursday, with the Nasdaq Composite falling over 350 points, and the S&P 500 dropping 1.18% to 6,859.69, indicating a weakening market sentiment amid growing investor concerns about the economic outlook.
- Sector Dynamics: Utility stocks rose by 2.4%, while information technology stocks fell by 1.5%, reflecting a market preference for defensive sectors as investors seek stable returns in light of economic uncertainty.
- Stock Highlights: American Electric Power Company, Inc. (NASDAQ:AEP) shares gained around 5% after reporting adjusted earnings of $1.19 per share, down from $1.24 a year ago but exceeding the Street estimate of $1.15, demonstrating the company's resilience in challenging conditions.
- Economic Data: U.S. initial jobless claims fell by 5,000 to 227,000, although slightly above market estimates of 222,000, indicating labor market resilience that could positively impact economic recovery.
See More
U.S. Stocks Mostly Higher in Morning Trade, Dow Up Over 200 Points
- Dow Jones Performance: The Dow Jones index rose over 200 points on Thursday, gaining 0.45% to reach 50,348.12, reflecting optimistic market sentiment towards economic recovery, which may attract more investor interest.
- Jobless Claims Data: U.S. initial jobless claims fell by 5,000 to 227,000, below market expectations of 222,000, indicating ongoing improvement in the labor market that could boost consumer confidence.
- Real Estate Sector Recovery: Real estate stocks gained 2.1% on Thursday, reflecting increased market confidence in real estate investments, which may promote further development in related industries.
- Commodity Market Fluctuations: Oil prices fell by 0.8% to $64.09, while gold prices dipped 0.4% to $5,079.00, indicating a cautious investor sentiment in the commodities market that could impact earnings expectations for related companies.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
BioRestorative Secures Patent Protection in Australia
- Patent Protection Enhanced: BioRestorative has received approval from IP Australia for its patent application covering the method of creating three-dimensional brown adipose-derived stem cell aggregates, further solidifying its market position in obesity and metabolic disease treatments.
- Technological Advantages Revealed: This patent provides the broadest protection for BioRestorative's ThermoStem® technology, aimed at developing safer and more effective cell-based therapies compared to GLP-1 drugs, showcasing the company's competitive potential in the rapidly growing therapeutic market.
- Global Strategic Expansion: CEO Lance Alstodt emphasized that securing this patent is a significant step in expanding the company's global IP portfolio, aimed at enhancing its leadership in stem cell therapies through continuous technological innovation and market protection.
- Clinical Trial Progress: BioRestorative is conducting a Phase 2 clinical trial for BRTX-100 targeting chronic lower back pain, and with the newly acquired patent, it is expected to accelerate its commercialization process in the regenerative medicine field.
See More
BioRestorative Closes Public Offering of 14.29 Million Shares
- Successful Public Offering: BioRestorative Therapies has closed its public offering of 14,285,715 shares at a price of $0.35 per share, raising approximately $5 million in gross proceeds, which reflects the company's funding needs and market confidence in the regenerative medicine sector.
- Clear Use of Proceeds: The net proceeds will be allocated to clinical trials for BRTX-100, pre-clinical research for the ThermoStem Program, and the development of its commercial biocosmeceuticals platform, indicating a strategic focus on product diversification and technological innovation.
- Regulatory Compliance: The registration statement for this offering was declared effective by the SEC on February 11, 2026, ensuring transparency and legality, which helps to enhance investor confidence in the company's operations.
- Broad Market Prospects: BioRestorative's lead product BRTX-100 is currently in Phase 2 clinical trials for chronic lower back pain, and with FDA IND clearance, it signals potential market opportunities and future growth in the regenerative medicine field.
See More
BioRestorative Closes $5 Million Public Offering of 14.3 Million Shares
- Funding Amount: BioRestorative successfully closed a public offering of 14.3 million shares, raising approximately $5 million in gross proceeds, which will be allocated to clinical trials for BRTX-100 and other R&D projects, thereby enhancing its competitive position in the regenerative medicine sector.
- Equity Structure: The offering was priced at $0.35 per share, with accompanying warrants issued at the same price, which are immediately exercisable and will expire in five years, providing the company with flexibility for future capital operations.
- Clinical Trial Progress: The company has initiated a Phase 2 clinical trial for BRTX-100 aimed at treating chronic lower back pain due to degenerative disc disease, which is expected to create new market opportunities for its product line and further drive company growth.
- Biopharmaceutical Platform: BioRestorative is also developing the ThermoStem program, utilizing brown adipose-derived stem cells to target obesity and metabolic disorders, with preliminary research indicating potential benefits in increasing caloric expenditure and reducing glucose and lipid levels, showcasing a broad market potential.
See More
U.S. Stocks Decline Midway, Nasdaq Drops Over 350 Points
- Market Performance: U.S. stocks traded lower midway through Thursday, with the Nasdaq Composite falling over 350 points, and the S&P 500 dropping 1.18% to 6,859.69, indicating a weakening market sentiment amid growing investor concerns about the economic outlook.
- Sector Dynamics: Utility stocks rose by 2.4%, while information technology stocks fell by 1.5%, reflecting a market preference for defensive sectors as investors seek stable returns in light of economic uncertainty.
- Stock Highlights: American Electric Power Company, Inc. (NASDAQ:AEP) shares gained around 5% after reporting adjusted earnings of $1.19 per share, down from $1.24 a year ago but exceeding the Street estimate of $1.15, demonstrating the company's resilience in challenging conditions.
- Economic Data: U.S. initial jobless claims fell by 5,000 to 227,000, although slightly above market estimates of 222,000, indicating labor market resilience that could positively impact economic recovery.
See More
U.S. Stocks Mostly Higher in Morning Trade, Dow Up Over 200 Points
- Dow Jones Performance: The Dow Jones index rose over 200 points on Thursday, gaining 0.45% to reach 50,348.12, reflecting optimistic market sentiment towards economic recovery, which may attract more investor interest.
- Jobless Claims Data: U.S. initial jobless claims fell by 5,000 to 227,000, below market expectations of 222,000, indicating ongoing improvement in the labor market that could boost consumer confidence.
- Real Estate Sector Recovery: Real estate stocks gained 2.1% on Thursday, reflecting increased market confidence in real estate investments, which may promote further development in related industries.
- Commodity Market Fluctuations: Oil prices fell by 0.8% to $64.09, while gold prices dipped 0.4% to $5,079.00, indicating a cautious investor sentiment in the commodities market that could impact earnings expectations for related companies.
See More
